Deerfield Management
Deerfield Management is a healthcare-focused investment firm that combines investment, intelligence, company-building, and philanthropy.
Last updated September 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Deerfield Management is a New York City-based investment firm focused on healthcare. According to the company, it was launched in 1994 and is dedicated to advancing healthcare through investment, intelligence, and philanthropy. Its stated aims include curing disease, improving quality of life, and reducing the cost of care. The firm says it manages more than $16 billion in assets as of December 2025. Deerfield describes its work as spanning the healthcare ecosystem, connecting people, capital, ideas, and technology. It provides flexible funding options to entrepreneurs and corporate partners and says its operational expertise and infrastructure can support the development of assets independently, on behalf of partners, or in collaboration with them. Its investment portfolio includes more than 200 private and public investments across life sciences, medical devices, diagnostics, digital health, and health services, from startups to mature companies. Beyond investing, Deerfield builds companies independently and with strategic partners. Its Deerfield Discovery and Development (3DC) operation is described as a company-building research and development engine where bench scientists and industry veterans work together. The company also points to Cure, a Deerfield affiliate and New York City facility housing life-science and healthcare companies, with laboratory space and scientific equipment used by portfolio companies and 3DC scientists. Deerfield’s stated model also includes intelligence activities such as healthcare technology and innovation work involving AI, data, and market research, alongside philanthropy through its New York City-based not-for-profit, the Deerfield Foundation. The firm’s public activity includes partnerships and alliances intended to advance healthcare-related technologies and services. Examples reported on its news page include work with Blue Cross Blue Shield of North Carolina to build Alo, a healthcare services platform for independent physicians, and an alliance with Hospital for Special Surgery focused on mobility and musculoskeletal health. Deerfield is therefore presented not only as an investment manager but also as a company builder and ecosystem partner. The supplied sources do not specify its founder, ownership structure, or a complete list of its executives.
History
Deerfield Management’s company history, as described in the supplied official materials, begins with its launch in 1994. The firm was established as an investment company dedicated to healthcare and now characterizes its mission as advancing healthcare through investment, intelligence, and philanthropy. Its stated aims are to cure disease, improve quality of life, and reduce the cost of care. The materials identify New York City as its headquarters but do not name a founder or provide a detailed account of the firm’s early years. The company presents its approach as broader than providing capital alone. It describes connecting people, capital, ideas, and technology across the healthcare ecosystem, with flexible financing for entrepreneurs and corporate partners. Deerfield also says that its operational expertise and infrastructure can support development of assets on its own, on behalf of strategic or corporate partners, or through collaboration with them. Its portfolio spans more than 200 private and public investments in life sciences, medical devices, diagnostics, digital health, and health services, at stages ranging from startup to maturity. The company states that it manages more than $16 billion in assets as of December 2025. Company building and research are part of this broader model. Deerfield identifies Deerfield Discovery and Development (3DC) as its company-building research and development engine, bringing bench scientists and industry veterans together. The company also describes Cure, a Deerfield affiliate in New York City that houses healthcare and life-science companies. Its facility includes laboratory space and scientific equipment that portfolio companies and 3DC scientists can use. An example of Deerfield’s partnership model is its work with Blue Cross Blue Shield of North Carolina to build Alo, a healthcare services platform intended to enable independent physicians to manage the business of medicine. Deerfield’s materials also describe an intelligence function involving healthcare technology and innovation, AI, data, and market research, and a philanthropic dimension associated with the Deerfield Foundation, a New York City-based not-for-profit. Recent items on its official news page illustrate continued activity through alliances and portfolio-company news. These include a strategic alliance with Metis TechBio concerning AI-driven protein therapeutics and in vivo immunotherapy, a collaboration with Hospital for Special Surgery focused on mobility and musculoskeletal health, and an announcement that portfolio company Nuvalent would be acquired by GSK. The company’s news page also reports its annual AML Summit and the 2026 ASH Peter Steelman Scholar Award recipient. The supplied sources do not establish additional historical dates, ownership details, or named company founders.
- 2026
ASH Peter Steelman Scholar Award recipient announced
- 2025
Reported assets under management
- 1994
Deerfield Management Company launched
Products and positioning
A healthcare-focused investment firm combining flexible capital, operational expertise, company building, healthcare intelligence, and philanthropy.
Deerfield Discovery and Development (3DC)
Deerfield’s company-building research and development engine, where bench scientists and industry veterans work together.
Cure
A Deerfield affiliate and New York City facility housing life-science and healthcare companies, with laboratory space and scientific equipment.
Alo
A healthcare services platform built with Blue Cross Blue Shield of North Carolina to enable independent physicians to manage the business of medicine.
Recent events
Lark Health closes $100 million Series D funding round[5]
Reported:
Lark Health announced that it had closed a $100 million Series D funding round led by Deerfield Management Company, with participation from other investors.
ARTMS announces $19 million Series A financing[6]
Reported:
ARTMS Inc. announced that it had raised $19 million in a Series A financing led by Deerfield Management Company, with additional investment from GHS Fund.
- Unconfirmed
Deerfield and Yeda sign research collaboration[7]
Reported:
Deerfield Management signed an agreement with Yeda Research and Development, the commercial arm of Israel’s Weizmann Institute of Science, to fund a collaboration of up to $130 million over 10 years. The new company, Orchard Innovations, will develop medicines based on Weizmann research.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/deerfield-management · Editorial policy · How profiles are compiled